Panzyga (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Panzyga, is an immunoglobulin presented as a intravenous solution for IV use. It replaces missing antibodies and is used in primary immunodeficiency disorders and certain immune‑mediated conditions. GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

GNH USA supplies Panzyga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide.

Panzyga is an immunoglobulin replacement product that acts within the humoral immune system to provide passive immunity.

- Primary immunodeficiency diseases (PIDD): restores deficient IgG levels and reduces infection frequency. - Secondary immunodeficiency (e.g., chronic lymphocytic leukemia, multiple myeloma): supports immune function when endogenous antibody production is compromised. - Post‑exposure prophylaxis for certain viral infections: provides immediate antibodies to aid viral neutralisation. - Immune thrombocytopenia (ITP) with secondary hypogammaglobulinemia: helps achieve hemostatic stability. - Hematopoietic stem‑cell transplantation conditioning: supplies needed immunoglobulins during engraftment.

Adverse reactions to Panzyga are primarily related to infusion and immune responses.

Common Side Effects: - Headache - Fever - Chills - Nausea - Fatigue - Myalgia

Serious or Rare Side Effects: - Anaphylaxis - Severe hemolysis - Acute renal failure - Thromboembolic events - Aseptic meningitis - Severe hypotension

Panzyga should be administered under medical supervision with attention to patient‑specific risk factors.

- Renal function monitoring: assess baseline creatinine and adjust infusion rate in renal impairment. - Cardiovascular status: monitor blood pressure and heart rate during infusion, especially in patients with cardiac disease. - History of allergic reactions: evaluate prior responses to blood products before initiating therapy. - Concomitant immunosuppressants: watch for enhanced infection risk. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Panzyga may interact with other agents that affect immune function or renal clearance.

Major Interactions (Avoid): - Live vaccines: concurrent administration can reduce vaccine efficacy and increase adverse events.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, amphotericin B): increase risk of renal injury. - High‑dose corticosteroids: may amplify infection susceptibility. - Anticoagulants: monitor coagulation parameters as immunoglobulin can affect platelet function. - Rituximab: may alter IgG kinetics and efficacy. - Diuretics: adjust fluid balance to avoid volume overload during infusion.